Relmada Therapeutics, Inc. (RLMD) earnings
RLMD earnings moved a median of -1.28% by the close. Quarterly and annual RLMD reports and results, each read against the price at its own news timestamp. Back to the RLMD overview →
30 measured RLMD earnings events.
Where these RLMD earnings landedvs 30 measured RLMD earnings reactions
| Middle 50% of RLMD earnings reactions | -4.54% to +0.92% |
|---|---|
| Median reaction (to close) | -1.28% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 RLMD earnings events with a measured close landed between -4.54% and +0.92%; 37% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -5.77% | -10.99% | |
| Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | -5.77% | -10.99% | |
| Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | Press release | -1.76% | -12.64% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +1.07% | +0.54% | |
| Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +1.07% | +0.54% | |
| Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 | Press release | -0.67% | +5.93% | |
| Form 10-K RELMADA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.23% | -6.62% | |
| Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 | Press release | -1.56% | -1.28% | |
| Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 | Press release | -4.23% | +1.92% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.77% | -1.28% | |
| Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC | Press release | +0.77% | -1.28% | |
| Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 | Press release | -2.81% | -2.44% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +0.13% | +0.93% | |
| Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.13% | +0.93% | |
| Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 | Press release | +0.23% | +6.67% | |
| Form 10-K RELMADA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -6.84% | -4.69% | |
| Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 | Press release | -1.14% | -4.09% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -1.85% | +0.92% | |
| Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -1.85% | +0.92% | |
| Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 | Press release | +1.61% | -2.64% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -4.98% | -28.35% | |
| Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -4.98% | -28.35% | |
| Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 | Press release | -2.30% | -2.59% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +1.28% | -2.56% | |
| Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | +1.28% | -2.56% | |
| Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 | Press release | +0.00% | +2.39% | |
| Form 10-K RELMADA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -19.51% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +2.66% | -0.66% | |
| Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | +2.66% | -0.66% | |
| Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 | Press release | +0.00% | +2.27% |
Keep exploring
More RLMD: analyst actions → · SEC filings → · RLMD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EVOTEC AG S/ADR (EVTCY) | 265 | 0.00% | 17% |
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.